Drug intelligence / Profile preview

isoalantolactone

Development stage
Preclinical
Modality
Small Molecules
Administration
In Vitro, In Vivo (research Use; No Human Administration Route Established)
01

Overview

**Isoalantolactone** is a natural sesquiterpene lactone of the eudesmanolide group, predominantly isolated from the roots of Inula helenium and other plants of the Asteraceae family[1][2]. It exhibits a broad range of pharmacological activities, including antitumor (notably proliferation inhibition, cell cycle arrest, ROS overproduction, apoptosis induction), anti-inflammatory (via NF-κB inhibition), antimicrobial, antihelminthic, antioxidant, and neuroprotective properties[1][3][5]. Mechanistically, isoalantolactone is known to induce apoptosis in cancer cells (for example, pancreatic cancer) by increasing reactive oxygen species and inhibiting the Wnt-β-catenin pathway as well as the AMPK-Skp2-Akt axis[3]. Its principal molecular pharmacodynamic actions are related to the modulation of oxidative stress and inhibition of specific intracellular signaling pathways linked to cell survival and inflammation[1][3][5].

Other names
(+)-isoalantolactoneiso-alantolactonisohelenin
02

Targets

mTOR (Mammalian target of rapamycin kinase)AKT (RAC-alpha serine/threonine-protein kinase)RELA (Nuclear Factor Kappa B Subunit p65)GSK3 (Glycogen synthase kinase 3 beta)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)

Beyond the preview

Go deeper on isoalantolactone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isoalantolactone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call